Johnson & Johnson yesterday was notified that the Food and Drug Administration now will require that the company add to the label of its COVID-19 vaccine a warning of a small, increased risk of Guillain-Barré syndrome, a rare but potentially serious neurological condition.

FDA notes that the window for the condition’s emergence is within 42 days of the vaccine’s administration. FDA said that because it has observed just 100 instances of Guillain-Barré among 12.8 million doses, with most people experiencing a full recovery, the risk is quite small compared to the risk of remaining unvaccinated against COVID-19. 

Related News Articles

Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…
Blog
Understanding potential costs is an important part of the patient experience when planning for care, and hospitals and health systems are committed to helping…
Headline
A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months…